Flexion Therapeutics, Inc.
Nov 28, 2017

Flexion Therapeutics to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference

BURLINGTON, Mass., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President, Commercial Operations, will participate in an analyst-led fireside chat at the Evercore ISI Biopharma Catalyst/Deep Dive Conference in Boston on Thursday, November 30, 2017, at 11:20 am ET.

To access the live webcast and subsequent archived recording of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.com/.

About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. Flexion was named one of the Boston Business Journal's 2017 Best Places to Work and one of the Top Places to Work in Massachusetts by The Boston Globe.

Corporate Contact:
Scott Young
Sr. Director, Corporate Communications & Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
syoung@flexiontherapeutics.com